Elimination of Gadolinium-Ethoxybenzyl-DTPA in a Rat Model of Severely Impaired Liver and Kidney Excretory Function, An Experimental Study in Rats

    loading  Checking for direct PDF access through Ovid

Abstract

RATIONALE AND OBJECTIVES

The authors investigated whether gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) can be eliminated in the absence of the two usual excretory pathways (urinary or biliary) and whether a remaining excretory pathway is able to compensate for impaired liver or kidney function.

METHODS

The study was performed using two groups of animals: group A animals underwent ligation of the common bile duct, and group B animals underwent ligation of the renal blood vessels. A dose of 0.1 mmol/kg Gd-EOB-DTPA or Gd-DTPA (control) was injected via a tail vein. Bile or urine were collected in fractions of 0 to 1, 1 to 2, 2 to 4, and 4 to 8 hours after administration of either contrast agent. At the end of the experiments, detainment of the contrast agents was determined by measurement of Gd concentrations.

RESULTS

Most of the Gd-EOB-DTPA was rapidly cleared from the body: 89.4% ± 7.5% of the injected dose within 4 hours after bile duct ligation (group A) and 87.0% ± 6.0% within 1 hour after ligation of renal vessels (group B). Eight hours after injection of Gd-EOB-DTPA, 3.0% ± 2.4% of the administered dose of this contrast agent was found in the car-casses of group A animals, and 1.3% ± 0.6% in carecasses of group B animals. By comparison, at 8 hours after injection, 1.9% ± 3.2% of the injected Gd-DTPA was found in the carcasses of group A animals (no statistical significant difference as compared with Gd-EOB-DTPA), and 96.3% ± 3.3% in carcasses of group B animals.

CONCLUSIONS

In the rat model, the magnetic resonance imaging contrast agent Gd-EOB-DTPA is rapidly and effectively eliminated by virtue of its dual-elimination pathway. The dysfunction of liver or kidney may be fully compensated by the remaining elimination pathway.

Related Topics

    loading  Loading Related Articles